Search

Displaying results 3841 - 3850 of 4233 in total
  1. Drug

    INM005

    go.drugbank.com/drugs/DB16499
    Investigational

    INM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984). Additionally, a retrospective cohort study investigated the ef...

  2. Drug

    NV1020

    go.drugbank.com/drugs/DB04969
    Investigational

    NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.

  3. Drug

    Alunacedase alfa

    go.drugbank.com/drugs/DB15736
    Investigational

    Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.

  4. Drug

    Piboserod

    go.drugbank.com/drugs/DB04873
    Investigational

    Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.

  5. Drug

    Zoledronic acid

    go.drugbank.com/drugs/DB00399
    ApprovedInvestigational

    Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hype...

  6. Drug

    Temoporfin

    go.drugbank.com/drugs/DB11630
    Approved

    Temoporfin is a photosensitizing agent used in the treatment of squamous cell carcinoma of the head and neck [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2001. It is currently available unde...

  7. Drug

    Amitifadine

    go.drugbank.com/drugs/DB05964
    Investigational

  8. Drug

    Piclamilast

    go.drugbank.com/drugs/DB01791
    Experimental

    It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma.

  9. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  10. Drug

    Evofosfamide

    go.drugbank.com/drugs/DB06091
    Investigational

    TH-302 is a nitroimidazole-linked prodrug of a brominated derivative of an isophosphoramide mustard previously used in cancer drugs such as ifosfamide, cyclophosphamide, and glufosfamide.